5% Weight Loss Achieved with New GLP-1 Pill: Terns Pharmaceuticals' TERN-601 Advances
Weight Loss Overview
Terns Pharmaceuticals is advancing its investigational GLP-1R agonist, TERN-601, into Phase II trials after early-stage results revealed significant weight loss benefits.
Key Findings from the Phase I Trial
- Mean Weight Loss: Achieved a placebo-adjusted weight loss of 4.9% after 28 days.
- Participant Results: 67% of those on the highest dose lost 5% or more of their baseline body weight.
- Tolerability: No treatment-related dose interruptions or meaningful liver enzyme changes were reported.
Impact on the Weight Loss Market
The increasing effectiveness of TERN-601 positions it competitively against other oral weight-loss medications, which face challenges such as dosing frequency and participant retention.
Future Developments
With the promising safety profile and efficacy indications, Terns plans swift advancement of TERN-601 into Phase II clinical development by 2025. Further data from the trial will be revealed at upcoming medical conferences.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.